Oncolytics Biotech Inc.
ONC.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -4.05% | 15.03% | -134.63% | 5.41% | 25.54% |
| Total Depreciation and Amortization | 111.67% | -303.11% | -0.59% | 257.37% | 113.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.95% | -34.35% | 523.87% | -16.69% | 48.93% |
| Change in Net Operating Assets | -1,720.03% | -96.12% | 1,303.72% | 79.16% | -24.19% |
| Cash from Operations | -11.65% | -35.27% | -22.12% | 16.45% | 28.23% |
| Capital Expenditure | -566.67% | 82.35% | -- | -- | 91.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -566.67% | 82.35% | -- | -- | 91.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 320.99% | 0.98% | -- | -- |
| Issuance of Common Stock | 212.06% | -43.17% | -29.94% | 46.22% | 100.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -269.99% | 174.90% | 77.23% | -491.67% | -135.60% |
| Cash from Financing | 163.68% | -3.89% | -22.63% | -7.16% | 52.85% |
| Foreign Exchange rate Adjustments | -106.21% | 116.41% | 142.68% | -457.69% | 114.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 108.93% | -97.38% | -237.42% | -12.74% | 90.72% |